Francis R

About Francis R

Clinical Operations: Global Phase trial execution, study management, portfolio delivery acrossoncology and rare disease• Drug Development: Protocol design input, feasibility, site selection, start-up, monitoring, database lock,regulatory submissions• Compliance & Quality: ICH-GCP/GVP adherence, risk-based quality management (RBQM), inspectionreadiness, data integrity, balanced risk approach• Collaboration: Matrixed cross-functional teams, distributed-authority environments, advice-seeking culture,\"working out loud\"• Strategic Impact: Outcomes-based work, rapid cycle optimization, high-impact prioritization, continuousimprovement, change management• Site Partnerships: Investigator-centric engagement, preferred partner positioning, enrollment optimization,site retention• Innovation: Digital trial enablement, decentralized models, patient-centric technologies, inclusive researchstrategiesTherapeutic Areas: Oncology (Hematologic Malignancies: AML, BPDCN; Solid Tumors: Breast Cancer, ESR1Mutations; Targeted Biologics: CD123)| Rare Diseases | Lysosomal Storage Disorders | Gene Therapy | Neurology | Cardiovascular

Experience

1. Senior Clinical Trial Manager

   Bristol Myers Squibb

   Apr 2024 — Present

   Directed Phase registrational oncology trials (CD123-targeted biologics, AML/BPDCN) across 60+ sitesspanning North America, Europe, and Asia, collaborating with Medical, Regulatory, Biostatistics, and DataManagement in distributed-authority model to achieve 100% milestone adherence and deliver mid- and long-term program outcomes on schedule.• Optimized $22M annual clinical operations budget by implementing KPI-driven CRO governance andstrategic vendor negotiations, realizing 10% cost reduction ($2.2M savings) while maintaining 98% eTMFcompleteness and inspection-ready quality standards.• Accelerated study start-up timelines by 15%(reduced from 12 months to 10.2 months average) through tieredfeasibility modeling and investigator-centric site selection that prioritized high-performing sites andeliminated low-value activities via rapid cycle optimization.• Enhanced patient and investigator experience by championing digital trial tools (eConsent, remotemonitoring, patient portals), achieving 40% improvement in patient experience scores and strengthening siteengagement to position BMS as preferred partner in competitive oncology landscape.

Education

• University of Port Harcourt

  Doctor of Philosophy - PhD, Pharmaceutical Sciences